Eyetronic

Eyetronic operates in a specialized segment of medical devices and neuroscience, centered on non-invasive electrical stimulation for vision-field impairment. Its core product, Eyetronic Therapy, uses individually tailored alternating-current stimulation for patients with glaucoma or optic-nerve diseases, while the broader EBS Therapy profile also addresses impairment associated with stroke and traumatic brain injury. The company’s differentiation is therefore clinical specialization rather than broad digital-health functionality: it combines patient-specific stimulation parameters with a treatment model delivered through clinical centers. Historical evidence of more than 1,200 patients, CE marking in 2013, and eight German treatment centers provides more market maturity than an early laboratory-stage concept. As a result, Eyetronic’s position can be assessed as a focused European neuro-ophthalmology device company, but not ranked reliably against specific competing products. Its €13.3 million in disclosed funding supports a substantial development history, though the last recorded financing was in 2017.

Eyetronic’s trajectory shows a long transition from research to clinical commercialization. The company was founded in 2007, followed by a €3.0 million Seed round in 2009 and a further €3.0 million Series B round in 2010. A second €3.0 million Series B round was recorded in 2013, alongside the reported CE marking of its stimulation device. The company began commercial treatment in 2014, then added €258,825 through equity crowdfunding in 2015 and €1.1 million in a 2015 venture round backed by Earlybird Venture Capital and HTGF. The last recorded financing was a €3.0 million Venture Round led by Norgine Ventures on Aug 9, 2017, bringing disclosed funding to $13,268,108. Operationally, the historical profile cited eight treatment centers in Germany, while the current employee signal identifies one featured business-development position and an estimated workforce band of 11–50. Public activity continued through a glaucoma-related post dated Mar 12, 2024, but there is insufficient evidence of recent hiring acceleration, new launches, or expansion beyond the established treatment network.